SCHEMBL2269212

SCHEMBL2269212

O=C(O)c1ccc(-c2ccc3c(c2)OCO3)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
ABCB1 P08183 1/20 0.50
CTNNB1 P35222 1/20 0.48
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 1/20 0.47
DHODH Q02127 1/20 0.47
MAPK1 P28482 1/20 0.46
FABP3 P05413 1/20 0.46
FABP4 P15090 1/20 0.46
FABP5 Q01469 1/20 0.46
POLB P06746 2/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8375405 0.83 TDP1 (0.52) KMT2AMEN1ABCB1ALDH1A1MAPT
SCHEMBL2270196 0.81 ABCB1 (0.49) RAB9AKMT2AMEN1ABCB1ALDH1A1
SCHEMBL1446429 0.81 MAPT (0.57) RAB9AKMT2AMEN1ALDH1A1MAPT
SCHEMBL17177737 0.80 DTYMK (0.49) KMT2AMEN1ABCB1ALDH1A1MAPT
SCHEMBL13374002 0.78 MAPT (0.67) RAB9AKMT2AMEN1ABCB1ALDH1A1
SCHEMBL5133283 0.78 ALDH1A1 (0.50) RAB9AKMT2AMEN1ABCB1ALDH1A1
SCHEMBL5193454 0.77 CRHBP (0.59) KMT2AMEN1ABCB1ALDH1A1MAPT
SCHEMBL27716703 0.77 ABCB1 (0.46) RAB9AKMT2AMEN1ABCB1ALDH1A1
SCHEMBL27716704 0.77 ABCB1 (0.46) RAB9AKMT2AMEN1ABCB1ALDH1A1
SCHEMBL12394331 0.77 PPM1B (0.54) RAB9AKMT2AMEN1CTNNB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 RAB9A 2238/4885KMT2A 1669/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.